Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Stefanick M L, Anderson G L, Margolis K L, et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrin F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111
   PubMed Web of Science ®Google Scholar
• Schoonen W GEJ, Joosten J WH, Kloosterboer H J. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55: 423–437
   PubMed Web of Science ®Google Scholar
• Cappelletti V, P, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995; 15: 2551–2556
   PubMed Web of Science ®Google Scholar
• Krämer E A, Seeger H, Krämer B, Wallwiener D, Mueck A O. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006; 27: 139–141
   Google Scholar
• Catherino W H, Jeng M H, Jordan V C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67: 945–952
   PubMed Web of Science ®Google Scholar
• Franke H R, Vermes I. Differential effects of progestagens on breast cancer cell lines. Maturitas 2003; 46(Suppl 1)S55–S58
   PubMedGoogle Scholar
• Cahill M A. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007; 105: 16–36
   PubMed Web of Science ®Google Scholar
• Meyer C, Schmid R, Scriba P C, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996; 239: 726–733
   PubMedGoogle Scholar
• Munton R P, Tweedie-Cullen R, Livingstone-Zatchej M, et al. Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007; 6: 283–293
   PubMed Web of Science ®Google Scholar
• Neubauer H, Clare S E, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10: R85
   PubMed Web of Science ®Google Scholar
• Peluso J J, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008; 149: 534–543
   PubMed Web of Science ®Google Scholar
• Brinton R D, Thompson R F, Foy M R, et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008; 29: 313–339
   PubMed Web of Science ®Google Scholar
• Andreotti P E, Cree I A, Kurbacher C M, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276–5282
   PubMed Web of Science ®Google Scholar
• Pfaffl M W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 2001; 29: e45
   PubMed Web of Science ®Google Scholar
• Ramakers C, Ruijter J M, Deprez R H, Moorman A F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003; 339: 62–66
   PubMed Web of Science ®Google Scholar
• Swiatek-De Lange M, Stampfl A, et al. Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia 2007; 55: 1061–1073
   PubMed Web of Science ®Google Scholar
• Peluso J J, Liu X, Saunders M M, Claffey K P, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008; 93: 1592–1599
   PubMed Web of Science ®Google Scholar
• Crudden G, Chitti R E, Craven R J. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006; 316: 448–455
   PubMed Web of Science ®Google Scholar
• Ansquer Y, Legrand A, Bringuier A F, et al. Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line. Anticancer Res 2005; 25: 243–248
   PubMed Web of Science ®Google Scholar
• Lee T-H, Seng S, Sekine M, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007; 4: 1101–1116
   Web of Science ®Google Scholar
• Wiebe J P. Progesterone metabolites in breast cancer. Endocr Relat Cancer 2006; 13: 717–738
   PubMed Web of Science ®Google Scholar
• Sauter E R, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997; 76: 494–501
   PubMed Web of Science ®Google Scholar